文献速递新生儿儿童感染

磷霉素治疗新生儿脓毒症的随机对照试验:药代动力学与钠负荷安全性

Randomised controlled trial of fosfomycin in neonatal sepsis: pharmacokinetics and safety in relation to sodium overload.
PubMed 文献 · Arch Dis Child · 2022-01-25

该单中心开放标签随机对照试验在肯尼亚Kilifi县医院纳入120例≤28天临床脓毒症新生儿,在标准抗菌治疗基础上加用静脉序贯口服磷霉素100 mg/kg每日两次、最长7天并随访28天。结果显示磷霉素对血清钠和胃肠道副作用无明显影响,不良事件发生率两组差异无统计学意义,模型提示多数患儿需150 mg/kg每日两次静脉给药才能达到药效学目标。

要点

  • 磷霉素未显示对血清钠或胃肠道副作用有影响。
  • SOC-F组与SOC组不良事件发生率分别为2.2与3.2事件/100婴儿日,差异无统计学意义。
  • 多数患儿需静脉150 mg/kg每日两次达药效学目标,<7天或<1500 g者减为100 mg/kg每日两次。

核心结论

  • 磷霉素作为价格可及、给药方案简单的新生儿脓毒症辅助治疗具有潜力,但需在更大住院新生儿队列中进一步研究其安全性。
  • 耐药抑制仅对最敏感病原体可实现,因此建议磷霉素与其他抗菌药物联合使用。

研究设计与样本

  • 单中心开放标签随机对照试验,地点为肯尼亚Kilifi县医院。
  • 2018年3月至2019年2月纳入120例≤28天、因脓毒症接受阿莫西林与庆大霉素标准治疗的新生儿。
  • 随机分配一半受试者加用静脉序贯口服磷霉素100 mg/kg每日两次、最长7天,随访28天。

主要发现

  • SOC-F组61例、SOC组59例,年龄0-23天。
  • 未观察到磷霉素对血清钠或胃肠道副作用的影响。
  • SOC-F组25例发生35次不良事件,SOC组34例发生50次,观察分别为1560与1565婴儿日,发生率为2.2 vs 3.2事件/100婴儿日,发生率差-0.95事件/100婴儿日(95%CI -2.1至0.20)。
  • SOC-F组4例、SOC组3例死亡。
  • 基于238份药代动力学样本建模,多数患儿需静脉150 mg/kg每日两次达药效学目标,<7天或体重<1500 g新生儿减为100 mg/kg每日两次。

关键数值与推荐

  • 磷霉素给药方案:静脉序贯口服100 mg/kg每日两次,最长7天。
  • 药代动力学建模推荐:多数患儿静脉150 mg/kg每日两次,<7天或<1500 g者100 mg/kg每日两次。
  • 不良事件发生率差-0.95事件/100婴儿日(95%CI -2.1至0.20)。

临床怎么用

  • 磷霉素可作为新生儿脓毒症价格可及、给药方案简单的联合治疗选择。
  • <7天或体重<1500 g新生儿按100 mg/kg每日两次给药,多数患儿需150 mg/kg每日两次达药效学目标。
  • 应与其他抗菌药物联合使用,不单独用于耐药抑制。

局限性

  • 单中心研究,样本量120例。
  • 安全性结论需在包括极早产或危重新生儿的更大住院新生儿队列中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess pharmacokinetics and changes to sodium levels in addition to adverse events (AEs) associated with fosfomycin among neonates with clinical sepsis. DESIGN: A single-centre open-label randomised controlled trial. SETTING: Kilifi County Hospital, Kenya. PATIENTS: 120 neonates aged ≤28 days admitted being treated with standard-of-care (SOC) antibiotics for sepsis: ampicillin and gentamicin between March 2018 and February 2019. INTERVENTION: We randomly assigned half the participants to receive additional intravenous then oral fosfomycin at 100 mg/kg two times per day for up to 7 days (SOC-F) and followed up for 28 days. MAIN OUTCOMES AND MEASURES: Serum sodium, AEs and fosfomycin pharmacokinetics. RESULTS: 61 and 59 infants aged 0-23 days were assigned to SOC-F and SOC, respectively. There was no evidence of impact of fosfomycin on serum sodium or gastrointestinal side effects. We observed 35 AEs among 25 SOC-F participants and 50 AEs among 34 SOC participants during 1560 and 1565 infant-days observation, respectively (2.2 vs 3.2 events/100 infant-days; incidence rate difference -0.95 events/100 infant-days (95% CI -2.1 to 0.20)). Four SOC-F and 3 SOC participants died. From 238 pharmacokinetic samples, modelling suggests an intravenous dose of 150 mg/kg two times per day is required for pharmacodynamic target attainment in most children, reduced to 100 mg/kg two times per day in neonates aged <7 days or weighing <1500 g. CONCLUSION AND RELEVANCE: Fosfomycin offers potential as an affordable regimen with a simple dosing schedule for neonatal sepsis. Further research on its safety is needed in larger cohorts of hospitalised neonates, including very preterm neonates or those critically ill. Resistance suppression would only be achieved for the most sensitive of organisms so fosfomycin is recommended to be used in combination with another antimicrobial. TRIAL REGISTRATION NUMBER: NCT03453177.

来源:Arch Dis Child,查看原文。版权归原作者所有。

引用

  1. Obiero CW, Williams P, Murunga S, et al. Randomised controlled trial of fosfomycin in neonatal sepsis: pharmacokinetics and safety in relation to sodium overload. Arch Dis Child. 2022. PMID: 35078765. doi:10.1136/archdischild-2021-322483

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。